Neveu, David
Mallett Moore, Tamala
Zambrano, Betzana
Chen, Aiying
Kürzinger, Marie-Laure
Marcelon, Lydie
Singh Dhingra, Mandeep
Funding for this research was provided by:
Sanofi
Article History
Received: 23 March 2023
Accepted: 23 August 2023
First Online: 27 September 2023
Declarations
:
: David Neveu, Tamala Mallett Moore, Betzana Zambrano, Marie-Laure Kürzinger, Lydie Marcelon and Mandeep Singh Dhingra are Sanofi employees and may hold stocks/shares. Aiying Chen was an employee of Sanofi at the time of the study was conducted, and held stocks during her employment at Sanofi; she is currently employed at Daiichi Sankyo, New Jersey, United States of America.
: This analysis is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. All clinical studies evaluating MenACYW-TT were conducted in accordance with the Declaration of Helsinki as well as in accordance with the Quality Standards of the International Conference on Harmonization Good Clinical Practices.